With the stated goal of curbing drug diversion and misuse, prescription drug monitoring programs (PDMPs) enable health care providers, law enforcement, and regulators to access patient medication profiles without their consent or prior authorization. In the context of the opioid crisis, the scope and reach of PDMPs has expanded rapidly. This has occurred largely without adequate attention to ethical and privacy considerations, including the particular concerns of LGBTQ patients. Anchoring the discussion in a legal challenge joined by two transgender men in Oregon, this presentation will interrogate the appropriate balance between state surveillance and patient privacy in the design and implementation of PDMPs.
Thursday, October 05, 201712:20 PM - 1:40 PMUCLA School of Law Room 1314
Lunch will be provided to those who RSVP before Thursday, September 28, 2017.